Market Herald logo


Be the first with the news that moves the market
  • Zelda Therapeutics is supplying its oil-based cannabis medicine for a government-funded clinical trial
  • The trial will enrol 600 patients who are suffering from advanced forms of cancer
  • Company Managing Director Dr Richard Hopkins said the supply agreement will generate the company’s first revenue from its branded product
  • Zelda’s share price is up nearly three per cent today and trading for 6.9 cents each

Zelda Therapeutics will have its oil-based cannabis medicine used in a government funded a clinical trial for cancer patients.

The CARE NSW trial is looking to enrol 600 people suffering from advanced forms of cancer.

“The focus on studying cannabis as a strategy to potentially alleviate symptoms in advanced cancer patients is very much aligned to our strategic interest in this area,” company Managing Director Dr Richard Hopkins said.

A number of medical companies specialising in cannabis treatments will be supplying products for the clinical trial, of which Zelda is one.

“The commercial supply agreement also represents a significant milestone for our shareholders, as it is expected to generate the Company’s first revenues from Zelda-branded TGA-TG093 compliant products,” Dr Richard added.

The trial is being conducted by the government funded group the Australian Centre for Cannabinoid Clinical and Research Excellence. The group was established to study cannabis’ therapeutic properties for use in Australia.

Following Zelda’s announcement to the market, shares in the company are up nearly three per cent and trading for 6.9 cents each.

ZLD by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.